Followers | 129 |
Posts | 4574 |
Boards Moderated | 0 |
Alias Born | 07/09/2011 |
Friday, June 01, 2012 9:44:50 PM
The study should have been completed sometime last month.
From clinicaltrials.gov:
Official Title: An Exploratory Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP) in Israel
Further study details as provided by Teva Pharmaceutical Industries:
Primary Outcome Measures: cost-effectiveness [ Time Frame: 18 months ] [ Designated as safety issue: No
To compare the cost-effectiveness of miRview™ mets test with conventional work-up in cancer of unknown primary (CUP) patients, by comparing total cost and time of the diagnostic process (including hospitalization time) from day 1 of the study to the decision on treatment program
Secondary Outcome Measures: compare the diagnostic performance [ Time Frame: 18 months ] [ Designated as safety issue: No ]
1) Evaluating the miRview™ mets results based on the clinical and
pathological work-up in all patients (retrospectively).
2) Evaluating the concordance between miRview™ mets result and the
diagnosis obtained by the standard work-up process.
3) Comparing the response to treatment between study groups.
4) Comparing overall survival between study groups
Biospecimen Retention: Samples Without DNA
Formalin Fixed Paraffin Embedded tumor tissue
Estimated Enrollment: 60
Study Start Date: May 2010
Estimated Study Completion Date: April 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
http://clinicaltrials.gov/ct2/show/NCT01...
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM